TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07871721: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3b Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) on Clinical Response and Inhibition of Radiographic Progression in Participants

Sponsor: Takeda · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 644 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07871721 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07871721 Rescue Dossier →